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The debate about how much to spend on health care is
one that preoccupies many, if not all, countries around
the world. In the UK, the NHS has enjoyed a period of
unprecedented real growth of spending, following a
commitment by the Prime Minister, Tony Blair, to raise
the proportion of UK gross domestic product spent on
health from the then 6.8% to the European national
average of 8.0% [1]. This promise was of course made
in the belief that increased spending would improve
outcomes, although the relationship between health-
care expenditure and health outcomes is complex
[2,3]. The study by Luce et al. published in this issue of
Value in Health makes a valuable contribution to this
debate by attempting to estimate the value of the
health improvements that have come about from
health-care expenditures in the United States in the last
two decades of the 20th century [4]. It adds to a small
but growing literature and is to be welcomed.
The estimates presented in the Luce et al. article
reﬂect calculations that are unavoidably weakened by
data limitations. Key assumptions, recognized by the
authors, include: the uncertainty around the value we
put on the units of health improvements; the uncer-
tainty around the proportion of the improvements that
are attributable to health-care expenditure, rather than
other health improving social changes; and the
assumed lags between spending and health-care bene-
ﬁts. In addition, there is the problem of splitting the
attributed returns between investments in health care
itself and investments in health-care research that
underpin them. As similar exercises are underway to
estimate the return on biomedical or health-related
research [5], there are dangers of double counting as
the returns in the form of health improvements are
claimed by both those estimating the returns to
research and those estimating the returns to health-
care services. All these details could be questioned and
no doubt will be the focus of debate and reﬁnement as
others go on to undertake similar calculations. It is to
be hoped that future analyses will be able to build on
stronger data and to be tested against a wider range of
alternative assumptions and methods. But to dismiss
the estimates provided here, on the grounds that they
are not perfect, would be churlish.
Rather, accepting that, for all their limitations, they
represent the best estimates we currently have, the
more important issue is to be clear what they can tell
(or suggest to) us, and what they cannot.
They remind us of some very simple points that can
often get lost in the debates about health-care spend-
ing. Not least of these is the fundamental point that
health care is intended to provide health improvements
and it is from these that its main value is derived. It is,
of course, also a major sector of the economy, and it
produces direct economic beneﬁt for those involved as
employees or investors. But therein does not lay its jus-
tiﬁcation. Similarly, the analyses remind us that we
should value health improvements for their intrinsic
value, difﬁcult though it is to measure, and we should
not just consider their effect on productivity.
The analyses also remind us that health improve-
ment is not the product of health care alone, and no
health-care system should delude itself into automati-
cally assuming that health is most efﬁciently improved
through health-care provision rather than education,
housing or efforts to improve the economic welfare of
the poorest groups in society. A clear research priority
for the future, as we focus more and more on public
health issues, is for comparative estimates of the value
of the health improvement from investment in these
other health-improving social investments.
More directly, the study shows us that in the United
States the average returns to investment on overall
expenditure on health-care services, and on Medicare
expenditure in four broad speciﬁc disease areas, have
been substantial. But the ongoing debate about health-
care spending has rarely, if ever, been about whether
we should spend all that we do or nothing at all, on
health care. Rather, it is about levels of spending:
whether we should extend or reduce spending on
health care. Using the latest Organization for Eco-
nomic Cooperation and Development data for 2003
[6] we might ask: was the 7.7% of gross domestic
product spent on health in the UK optimal or would
either 6% or 10% have represented better targets?
Was the 15% spent in the United States too little or too
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much? While, the ﬁrst Luce et al. analysis is reassuring
that on average across all the additional spending on
health care between 1980 and 2000, each dollar is
contemporaneously associated with health gains val-
ued somewhere between $1.48 and $1.85, perhaps at
the margin there are diminishing, or possibly even neg-
ative, returns to additional spending. As economists,
we warn our students not to focus on average returns
but rather to estimate marginal or incremental returns.
Their second analysis, looking at four main areas of
health provision, disaggregates the data a little and
suggests that the returns to investment in health care
relating to breast cancer have been more than four
times as high as the returns to treatment for heart
attack. So can we interpret this as an indication that
we should spend more on breast cancer (where the
returns have been highest), or might we infer that we
should spend more on heart attack (where there still
remains considerable potential to beneﬁt)? The fact is
that we simply cannot tell from a study like this. Not
only does it not tell us anything about the margin, but
past  returns  on  investments  (as  the  small  print  at
the bottom of the ﬁnancial advertisements dutifully
reminds us) may not be a guide to the future.
The returns to speciﬁc innovations, again taking the
estimates at face value, emphasize the variability of
rates of return on, or cost-effectiveness of, different
interventions. The sample of returns quoted is clearly
neither random nor representative, but they remind us
that in some cases returns do not justify the use of the
innovation, and in other cases they suggest that some
innovations may be exceptionally good investments of
the public’s health-care dollars. These cost-effective-
ness studies of innovations generally will have esti-
mated returns for the innovation optimally provided
and well targeted to appropriate patient groups. But,
much of the increase in health-care spending in the
period in question would not have been on innova-
tions, but on providing well-established health care in
greater quantities but often for broader and less cost-
effective indications than initially. So the ﬁgures for the
returns to individual innovations should remind us
how variable are these returns to new activities at the
margin of health care and how zealously all countries,
including the United States, need to guard against the
use of relatively cost-ineffective technologies, or cost-
ineffective application of otherwise relatively effective
technologies [7].
Finally, we must all remember that none of us seeks
to maximize health alone unconstrained by our other
objectives. As individuals making private investment
and consumption choices or as public policymakers
investing tax-dollars or social insurance receipts on
behalf of others, have to judge whether, at the margin,
we value the return on investments in health or in
other aspects of our utility functions more highly.
None of this is to suggest that the article published
here, and the broader stream of research that it repre-
sents, are not valuable stepping stones to a better
understanding of these issues. But in our enthusiasm to
be advocates for health-care spending, let us not over-
state what we know and hide what we do not know.
Nor should we forget to remind policymakers,
whether they are Secretaries of State for Health or
CEOs of major manufacturing companies [8], that the
average tells us nothing about the margin.
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